Altimmune finds itself at a crossroads this week, presenting its investment case at the H.C. Wainwright Global Investment Conference while simultaneously confronting a wave of shareholder litigation. The dual pressures contributed to the stock’s 1.85% decline yesterday, closing at $3.71 per share.
Legal Proceedings and Investor Deadlines
Multiple law firms, including Pomerantz LLP, Rosen Law Firm, and The Gross Law Firm, have announced ongoing class action investigations against the biopharmaceutical company. The litigation centers on allegations that Altimmune provided misleading information regarding results from its IMPACT Phase 2b MASH study.
The controversy stems from the June 26, 2025, data release that triggered a dramatic 53.2% single-day collapse in share value, plummeting from $7.71 to $3.61. Plaintiffs allege the company misrepresented the significance of fibrosis reduction data due to an unexpectedly strong placebo effect.
Investors who purchased securities between August 10, 2023, and June 25, 2025, have until October 6, 2025, to petition the court for lead plaintiff status in the proceedings.
Counterbalancing Developments
Against this legal backdrop, Altimmune’s management team is engaging with investors at the H.C. Wainwright conference today. The company scheduled a fireside chat presentation for 8:30 a.m. Eastern Time to discuss pipeline developments and corporate strategy.
Should investors sell immediately? Or is it worth buying Altimmune?
The conference appearance represents an opportunity to shift focus toward recent positive developments. In August, the company reported encouraging quarterly results and received FDA Fast Track designation for pemvidutide in treating alcohol use disorder.
Analyst Sentiment Remains Positive
Despite the legal overhang, equity researchers maintain constructive outlooks on Altimmune’s prospects:
- Thirteen analysts maintain “Buy” or equivalent ratings
- The consensus price target stands at $17.40
- Significant upside potential exists relative to current trading levels
From a technical perspective, shares found support at yesterday’s closing price of $3.71. Trading parameters for the current session are expected between $3.60 and $3.82.
Market observers indicate that forthcoming data releases will be crucial for directional movement. The 48-week results from the IMPACT study, along with Phase 2 testing for alcohol use disorder and alcohol-associated liver disease, represent key catalysts for future valuation.
Ad
Altimmune Stock: Buy or Sell?! New Altimmune Analysis from February 7 delivers the answer:
The latest Altimmune figures speak for themselves: Urgent action needed for Altimmune investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.
Altimmune: Buy or sell? Read more here...
